Merck to offer 100 million settlement in NuvaRing lawsuits

Merck to offer $100 million settlement in NuvaRing lawsuits
Merck will pay $100 million to settle thousands of lawsuits over the company's NuvaRing birth control device, according to insiders.

(HealthDay)—Merck will pay $100 million to settle thousands of lawsuits over the company's NuvaRing birth control device, according to insiders.

The will be announced Friday and provide an average payout of more than $58,000 per case, two people familiar with the told Bloomberg News. They did not want to be identified because they hadn't been authorized to talk publicly about the accord.

The deal will resolve several thousand cases in federal and state courts in Missouri and New Jersey. Women accused Merck of selling NuvaRing even though the company knew that the device put them at higher risk for than products from other companies.

A Merck spokeswoman declined to comment on the settlement, Bloomberg reported.

More information: Other Health Highlights: Feb. 7, 2014

add to favorites email to friend print save as pdf

Related Stories

Germany's Merck to buy materials supplier AZ

Dec 05, 2013

Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion).

Belgium's Ablynx in Merck cancer research tie-up: firm

Feb 03, 2014

Belgian biotechnology company Ablynx said on Monday it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros ($2.3 billion).

Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

Merck: FDA wants more studies of insomnia drug

Jul 01, 2013

Drugmaker Merck & Co. says federal regulators have ruled that they won't approve high doses of its experimental insomnia medication because of concerns about their safety.

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.